Roche Archives - Page 4 of 8 - DelveInsight

Roche

Healthcare scenario in MENA region
Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players

The Middle-East and North-Africa region (MENA), which encompasses some of the world’s wealthiest economies, extends unparalleled opportunities to multinational corporations with expertise in medic...


pharma news
Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy

Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion. Roche has agreed to license in Sarepta’s gene therapy ‘SRP-9001’ for Duchenne muscular dys...


Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval

Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS.Reblozyl ((luspater...


Pharma News
Novartis buys Medicines Co. for USD 9.7 Billion

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market.Under the terms of the deal, Novartis will pay U...


Recent Pharma News
Roche’s Tecentriq combo proves effective in Bladder cancer

Roche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy.The drug...


Lupus Nephritis
Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis

The US FDA has in a recent move granted Roche’s Gazyva Breakthrough Therapy Designation (BTD) for adults with lupus nephritis.Gazyva (obinutuzumab) is an anti-cancer ("antineoplastic" or "cyto...


breast cancer emerging drugs
How HR+/ HER2-Breast Cancer emerging drugs will transform the market?

More than a dozen companies have shifted their focus towards the Hormone Receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer therapeutic area. Some of ...


HR+/HER2- Breast Cancer
Global HR+/ HER2- Breast Cancer Market Scenario

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast ca...


Systemic sclerosis
FDA approves Ofev for interstitial lung disease

Recently, the US FDA has approved a new drug therapy to treat adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. Ofev (nintedanib) capsules, t...


HER2-Positive Breast Cancer
Metastatic HER2-Positive Breast Cancer

Breast cancer is not a single disease leading to abnormal cell division in breast tissues. In the United States, it is estimated that more than 40,000 women will die from breast cancer in 2017. Ac...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.